STOCKS TELEGRAPH

Tag: Atossa Therapeutics

  • 3 Stocks to Watch Closely: Atossa Therapeutics Inc (ATOS), AlphaTON Capital Corp (ATON), Hillcrest Energy Technologies Ltd. (HLRTF)

    3 Stocks to Watch Closely: Atossa Therapeutics Inc (ATOS), AlphaTON Capital Corp (ATON), Hillcrest Energy Technologies Ltd. (HLRTF)

    As financial markets continue to evolve, investors are refining their approach to evaluating opportunities in the emerging and small-cap segment. Movements in share valuations and fluctuations in trading activity often serve as indicators of shifting confidence. Monitoring volatility patterns, recent market performance, and the prevailing investment climate helps reveal how these companies are reacting to ongoing economic and market changes.

    Atossa Therapeutics Inc (ATOS)

    Atossa Therapeutics Inc (NASDAQ: ATOS)‘s stock price has plunged by 2.84%relation to the previous closing price of $4.57. Nevertheless, the company has seen a -0.42% plunge in its stock price over the last five trading sessions, with a -11.99% decline in the past month and a -60.80% plunge in the past quarter. The volatility ratio for the week is 8.81%, and the volatility levels for the past 30 days are at 8.87% for ATOS. The simple moving average for the past 20 days is 6.71% for ATOS’s stock, with a -58.00% simple moving average for the past 200 days.

    ATOS Trading at -32.33% from the 50-Day Moving Average

    After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.71% of loss for the given period. Volatility was left at 8.87%; however, over the last 30 days, the volatility rate increased by 8.81%.

    AlphaTON Capital Corp (ATON)

    AlphaTON Capital Corp (NASDAQ: ATON) has experienced a rise in its stock price by 1.84% compared to its previous closing price of $0.39. However, the company has seen a gain of 4.09% in its stock price over the last five trading days, with a -25.52% drop in the past month and a -75.81% drop in the past quarter. The volatility ratio for the week is 13.09%, and the volatility levels for the past 30 days are 12.44% for ATON. The simple moving average for the past 20 days is -8.22% for ATON’s stock, with a -90.74% simple moving average for the past 200 days.

    ATON Trading at -35.53% from the 50-Day Moving Average

    After a stumble in the market that brought ATON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with 97.48% of loss for the given period. Volatility was left at 12.44%; however, over the last 30 days, the volatility rate increased by 13.09%.

    Hillcrest Energy Technologies Ltd. (HLRTF)

    Hillcrest Energy Technologies Ltd. (HLRTF) has been strengthening its European presence by appointing Otmar Bitsche as Vice President of European Business Development. With more than three decades of experience in EV powertrain systems, including leadership roles at Porsche, Bitsche is expected to help drive the adoption of Hillcrest’s ZVS technology among European automotive manufacturers and industrial partners.

    Market Momentum

    As of March 10, HLRTF is trading at $0.1249, reflecting a 4.66% daily decline. Despite the drop, the company’s stock remains significantly above its 52-week low of $0.0490, demonstrating the volatility typical of emerging technology companies.

    Strategic Expansion

    Hillcrest’s collaboration with Systematec GmbH provides engineering support and validation capabilities aimed at accelerating integration of its inverter technology into automotive and industrial applications.

    Sector Outlook

    Europe remains one of the largest markets for EV development and electrification initiatives, creating opportunities for innovative power electronics solutions.

  • Atossa Therapeutics (ATOS) Stock Shows Little Substance

    Atossa Therapeutics (NASDAQ: ATOS) is an early-stage biopharmaceutical that is slowly making progress with a Covid-19-related treatment. ATOS stock has been declining, given that investors have little to latch onto at the present moment.

    Bleak Financial Outlook for ATOS

    Atossa Therapeutics (ATOS) has not had a good year in the stock market, with ATOS stock price decline of over 75% seen in the last 12 months alone. This lack of confidence by market participants comes as a direct result of poor fundamentals, and little substance to hold on to that would warrant investing one’s capital in. Its EPS of -$0.05 marginally beat the analyst consensus of -$0.06. Moreover, its operating expenses saw a reduction from $7,000 to $6,595 on a year-on-year basis. Its cash holdings have decreased since the prior quarter from $131,100 to $125,500. This clearly points to financing challenges for large-scale drug development.

    Atossa Therapeutics Pipeline and Progress

    Financials, at this point of the company’s lifecycle, do not reflect the inherent value it holds, which is typical of an early-stage bio-pharmaceutical. The company has initiated a number of procedures in the development process of its AT-H201 drug candidate, after the completion of parts B and C of its phase 1/2a clinical trial. Although this stage of the development process is far too early for an opinion to be formed about the drug’s viability, it is progress nonetheless. To add, Atossa also entered into an agreement with a US venture capital firm that will assist the company in relation to operations, personnel, and intellectual property.

    Conclusion

    At present, ATOS stock has little substance going for it, the result of which the market does not have a reason to be confident about its prospects. However, progress is slow, which is better than its affairs being at a complete standstill.

  • Atossa Therapeutics, Inc. (ATOS) stock is declining in Pre-Market today: Why is it so?

    Atossa Therapeutics, Inc. (ATOS) stock is declining in Pre-Market today: Why is it so?

    Shares of the Atossa Therapeutics, Inc. (ATOS) stock were declining in the pre-market trading session today on July 20, 2021, after dropping as much as 13.33% at the previous closing. The ATOS stock price saw a drop of 0.51% to reach $3.88 a share and the trading volume was 24,759,902 as of this writing. Let’s understand why ATOS stock is bearish today.

    What’s Happening?

    Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery and development of medicines for oncology and infectious diseases. There seems to be no news related to Atossa Therapeutics in today’s date to justify the bearish sentiment. No press release or announcement has been made to support the declining per share price of the ATOS stock. For now,it is better to look at some recent events of ATOS stock.

    Atossa fight against Covid-19:

    Though many western countries have made significant progress in vaccinating their population, still Covid-19 is the major health concern due to its evolving variants that are more deadly. Atossa is developing AT-H201 in order to treat patients suffering from moderate covid-19. Attosa is now planning to treat a group of 60 mixed patients that are either recovered or moderately ill hospitalized covid-19 patients in a phase ½a placebo-controlled study by utilizing the combination of blood thinner Heparin and the anti-inflammatory N-acetylcysteine, with AT-H201.

    The Analyst Opinion:

    Maxim analyst Jason McCarthy considered the combination of N-acetylcysteine and Heparin as “intriguing”. McCarthy thinks that the AT-H201 is the only reason that makes ATOS stock more attractive as far as investment in stocks is concerned. He rated the ATOS stock “buy” and set a $7 target price. The ATOS stock is weighed by only two analysts, and both rated the stock “ buy”.

    Performance in June:

    ATOS stock had made significant progress in June 2021 as it became part of Russell 2000 and Russell 3000 indexes. Moreover, the Swedish Medical Product Agency (MPA) approved the commencement of  Endoxifen’s second phase clinical trial study. Endoxifen is used to treat the mammographic breast density (MBD) that is affecting 10 million women in the U.S alone.

    Wrap Up:

    The ATOS stock is declining in the stock market without any obvious reason. Such rises and falls don’t affect the long-term investors who mainly focus on stock’s overall growth and developments.

  • Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    In the premarket trading session, at last check, Atossa Therapeutics Inc. (ATOS) stock had surged by 2.55% to $6.04. ATOS’s stock previously closed the session gaining 10.09% to $5.89. The ATOS stock volume traded 14.72 million shares. In the past week, ATOS shares have moved up by 27.49%. In the past three and six months, the ATOS stock has jumped up by 135.60%, and 584.72% respectively. Furthermore, Atossa therapeutics Inc. is currently valued in the market at $711.65 million and has 120.82 million outstanding shares.

    Here’s what you need to know about Atossa Therapeutics Inc.

    Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the developing and designing of unique innovative treatments and medicines for the unmet needs of the health market. The company specifically focuses on the platform of development and design of medicines for the areas of oncology and infectious disease.

    The company has created programs to fight breast cancers, improve lung functions and has therapy programs as well for the treatment of cancers. The lead candidate program is known as Endoxifen for breast cancer treatment which is in Phase II of clinical trials and is a metabolite of tamoxifen. AT-H201 and AT-301 are proprietary drugs used for the treatment and recovery of lung function in COVID19 patients. ATOS stock also participates and supports research for treatments like potential treatment of breast cancer through cytokine-coated nanoparticles in partnership with Dana-Farber Cancer Institute Inc. Furthermore, the company was previously known as Atossa Genetics Inc up till January 2020 and is founded in 2008. The Atossa headquarters is in Seattle Washington.

    How has Atossa’s operations been doing lately?

    The month of June has been very progressive and successful for ATOS stock and Atossa’s clinical study operations. On 16th June 2021, the company was announced to be part of the Russell 2000 and Russell 3000 Indexes. Atossa is primarily focusing on Breast cancer and COVID19-related treatments. There is a preliminary list of additions that were posted on 4th and 14th June 2021, informing that the official integration will be concluded on 2021 Russell Indexes’ annual reconstitution. The implementation will be effective after US market opens on June 28, 2021.

    On 11th June 2021, ATOS stock received approval from the Swedish Medical Product Agency (MPA) which encourages the initiation of Endoxifen’s second phase clinical trial study. Endoxifen will be used for the treatment and reduction of mammographic breast density (MBD) which is affecting more than 10 million women in the US and scattered across the globe. Increased mammographic breast density results in the difficulty of detecting cancer and increases the development of breast cancer risk.

    Furthermore, Atossa Therapeutics announced the final data of the phase 2 study of oral Endoxifen. This study was used to test the efficacy and safety of the administration of the dose between the time of diagnosis of breast cancer and surgery. The primary endpoint met result showed Ki-67 reduction by an average of 25.6% and has shown clinically meaningful results because these statistics according to to other studies showed a result of improved survival rate.

  • Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Shares of Atossa Therapeutics, Inc. (ATOS) stock continued the uptrend in today’s market on May 3, 2021, after gaining 0.43% at the previous closing. ATOS stock price saw a surge of 6.01% a share to reach $2.47 a share as of this writing. Atossa CEO Dr. Steven Quay’s participation in a panel discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021, is the only recent news announced by the Atossa stock on April 30, 2021. Let’s discuss more of it.

    What’s happening?

    Atossa Therapeutics, Inc being a pharmaceutical company engages in the discovery and development of medicines related to oncology and infectious diseases. Individuals are eyeing the upcoming panel discussion this week which will last for three days. Many speakers of reputed venture investment funds will attend the conference.

    Previous Development:

    ATOS stock on April 08, 2021, did announce the beginning of treatment of ovarian cancer patient with Atossa’s proprietary oral Endoxifen following the approval of expanded access by the U.S.A Food & Drug Administration for Endoxifen in the “Safe to Proceed” letter. Dr. Barbara Goff, Surgeon-in-Chief treated the patient at the University of Washington Medical Center. The use of Enodxifen was restricted only to that patient and the initial testing showed exceptional results of tumor response after the combination of Endoxifen and alpelisib.

    Financial View of ATOS stock:

    • ATOS stock announced its financial results for the fiscal year 2020 according to which Atossa stock had no source of sustainable revenue and no associated cost of revenue at the end of the year 2020.
    • ATOS stock reported operating expenses of $14,607,000 for the year 2020 which represents a 15% decrease as compared to the operating expenses of 2019.
    • Research and development expenses for ATOS stock were reduced by 1% as compared to 2019 to drop at $6,608,000.Stock-based compensation of $2,214,000 was mainly responsible for this decrease.
    • General and administrative expenses for ATOS stock were totaled $7,999,000 for 2020 representing a decrease of 25% as compared to 2019. The main reason for this decrease was Stock-based compensation of roughly $3,610,000.
    • ATOS stock reported cash, cash equivalents, and restricted cash of $39.7 million at the end of the year 2020.

    Conclusion:

    Things are going well for ATOS stock as far as market sentiment is concerned and the upcoming conference discussed above will further decide the future of the ATOS stock.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

  • Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock dropped down -38.46 to $0.88 in the Early hour’s session today after a clinical-stage biopharmaceutical corporation looking to find and grow novel drugs in areas of substantial unmet medical need with a current emphasis on breast cancer and COVID-19, revealed the offering of an underwritten public offering with estimated cumulative gross proceeds of $20.0 million before deducting underwriting discounts, commissions.

    The shares issued by the Corporation comprise of I 14,575,000 shares, each consisting of one share of common stock and 0,75 Warrants for the acquisition of one share of common stock for $1.00 each unit and (ii) 5,425 units, each consisting of one share of Series C Convertible Preferred Stock with a fixed valuation of $1,000 each share and convexed. The Warrants will have an exercise price of $1.00 per share, will be automatically enforceable, and will expire four years from the date of issue.

    Shares of Common Stock, Preferred Stock, and associated Warrants can only be acquired together in the bid but will be distributed separately and will be instantly separable upon issuance. According to the standard closing terms, the offer is scheduled to close on or around 11 December 2020.

    Following the deal, Maxim Group LLC serves as the sole book manager.

    Atossa Therapeutics has given Maxim Group LLC a 45-day option to buy up to an extra 3,000,000 shares of Common Stock and Warrants to purchase up to an additional 2,250,000 shares of Common Stock a public offering price of fewer discounts and commissions.

  • Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) a biotech giant with a focus on breast cancer and COVID-19, today announced blinded results from its Phase 1 clinical trial using Atossa ‘s patented AT-301, delivered through a nasal spray.

    In this study, AT-301 was found to be safe and well-received at two different dose levels over 14 days, in both single and multiple-dose formulations. For patients experiencing symptoms with COVID-19, AT-301 is being created to be used at home. In order to treat COVID-19 at home, there are currently no FDA-approved therapies.

    Atossa helps to determine potential collaborators who are designing diagnostic tests for COVID-19 so that AT-301 nasal spray can be co-developed and promoted with the purpose of making accessible AT-301 therapy when a person shows symptoms and test positive for the coronavirus.

    Atossa plans to further improve its nasal spray to prevent infection with COVID-19, specifically for all of those living in high-risk environments such as COVID-19 infected patients, health care workers, and emergency respondents and teachers.

    Although some manufacturers are still developing a vaccine for SARS-CoV-2, Atossa considers that therapies such as AT-301 provide a major market opportunity. The production and availability of conventional vaccines can also take years. Surveys have found that when a conventional vaccine is initially available, many people would not receive a vaccine 100%, particularly if multiple types of Coronavirus appear.

    The stock of the Healthcare sector started trading yesterday at $1.33. During the session, it climbed to $1.49 and dropped to $1.25 before closing at the price of $1.36. The stock with a market capitalization of $14.47M had a volume of 280.54 k.